A quarter of people with skin psoriasis (inflammation and thickening of parts of the skin) can get a form of arthritis called psoriatic arthritis. Occasionally the arthritis can start before the skin condition.


The main pathology in psoriatic arthritis is inflammation at the interface where ligaments or tendons insert into bone. Inflammation of this area is called enthesitis. This often results in pain and swelling of the nearby joint. When the tendons in the fingers that insert near the nail bed are involved it can cause abnormality in the nail.

Psoriatic arthritis can affect just one area, a few joint and tendon areas or it can involve many parts of the body all at once. An inflammatory condition of the eye called iritis and inflammatory bowel disease often co-exist and are thought to be part of the same disease process. 


The main recognized risk factors are a personal or family history of skin psoriasis. About 40% of people with psoriatic arthritis will have a family member with skin psoriasis or psoriatic arthritis. Other risk factors include obesity and smoking. Anxiety and depression are also very common co-morbid conditions. 


Treatment depends on the severity of the disease and can range from joint injections, anti-inflammatories and disease modifying medication such as methotrexate, salazopyrin or leflunomide. In the more severe cases - anti-TNF biological disease modifying drugs such as adalimumab, etanercept and infliximab can be used.  As of May 2021, secukinumab has also been funded by Pharmac in New Zealand as a first line biological treatment option as an alternative to the anti-TNF medications.  

There are some other treatment options such as apremilast and ustekinumumab  available but these medications are not yet funded by Pharmac in New Zealand. They are available for patients who have the financial resources to pay for them.

In those who are overweight, weight-loss may improve the effectiveness of medical therapy.

© Copyright 2024 Auckland Rheumatology and Sports Medicine Limited